TheraRadar
← Back
Data updated: Jun 17, 2026

VALEANT INTL

Big Pharma

VALEANT INTL is a major pharmaceutical company focused on Dermatology, Immunology, Gastroenterology.

1952
Since
34
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
3 Small Molecules

VALEANT INTL's Key Drugs

VALEANT INTL's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

VALEANT INTL's Recent FDA Approvals

New NDA/BLA approvals for VALEANT INTL over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

VALEANT INTL's Therapeutic Areas

VALEANT INTL's approved drugs and pipeline span 3 therapeutic areas, led by Dermatology and Immunology, across 0 biologic and 3 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Dermatology 50%
2 drugs
Immunology 25%
1 drugs
Gastroenterology 25%
1 drugs

VALEANT INTL's Top Competitors

VALEANT INTL's closest competitors by therapeutic-area and drug-target overlap include BAUSCH, APOTHECON, and Pfizer. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

VALEANT INTL Pipeline Snapshot

Active clinical trials for VALEANT INTL across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Dermatology pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling